Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

OAKLAND, Calif.--(BUSINESS WIRE)---- $AMLX #AMLX--Gibbs Law Group reminds investors that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023. Investors are encouraged to contact our firm before the April 9, 2024 lead plaintiff deadline to discuss their options for participation in the lawsuit. What Should Amylyx Pharmaceuticals Investors Do? If you investe.

Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / March 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

IMPORTANT INVESTOR DEADLINE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW ORLEANS , March 15, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 9, 2024 to file lead plaintiff applications in a securities class action lawsuit against Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX), if they purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period").

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=71203&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by April 9, 2024 Deadline to Join Class Action Against Amylyx Pharmaceuticals, Inc. (AMLX)

ACADIA Pharma

West Pharmaceutical Services

Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it's important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype.

3 Pharma Stocks to Sell in March Before They Crash & Burn

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors.

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

NEW YORK , March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc.. Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=70874&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Pharmaceuticals, Inc. Lawsuit - AMLX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=70727&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 – AMLX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=70711&wire=1 or contact Joseph E. Levi, Esq.

Amylyx Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 – AMLX

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=70704&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) - April 9, 2024 Deadline to Join – Contact Levi & Korsinsky

NEW YORK , March 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, both dates inclusive (the "Class Period"), of the important April 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Amylyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

NEW YORK , March 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc.. Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.

Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.

LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW ORLEANS , March 8, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 9, 2024 to file lead plaintiff applications in a securities class action lawsuit against Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX), if they purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of New York.

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.

Amylyx's ALS Drug Fails Trial, Raising Questions About Company's Future

Amylyx stock crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in its pivotal study.

Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=70042&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.

Amylyx's ALS drug fails in late-stage confirmatory study

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA™ in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its primary endpoint of reaching statistical significance (p=0.

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=69626&wire=1 or contact Joseph E. Levi, Esq.

News for Amylyx Pharmaceuticals Stock (AMLX)